Network News
Endometriosis, menopause, ovarian cancer – still poorly researched and often misdiagnosed. Ângela Gonçalves combines AI, molecular biology, and clinical findings to develop non-invasive tools for early detection, personalized care, and healthier aging – directly challenging gender bias in medicine. The scientist from the DKFZ-Hector Cancer Institute at the University Medical Center Mannheim is the winner […]
read more
Fraunhofer IGB receives approximately three million euros in funding to establish a biofabrication center
The manufacture of complex biological products and tissues is groundbreaking for biomedicine, for example in replacing diseased tissue or as an alternative to animal testing, but also for the biotechnological production of cultured meat. The state of Baden-Württemberg and the EU are investing in equipment at the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB […]
read more
SPT Labtech and Alithea Genomics Collaborate to Automate Ultra Sensitive Single-Cell Transcriptomic Workflows
Cambridge, UK, and Lausanne, Switzerland, 05 November 2025: SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, and Alithea Genomics, a pioneer in the field of large-scale RNA sequencing and transcriptomics, today announced a collaboration to provide an automated solution for single-cell transcriptomics. The collaboration integrates Alithea […]
read more
SPT Labtech and 10x Genomics Partner to Automate Single Cell Workflows
Melbourn, UK, and Pleasanton, California, US, 14 October 2025: SPT Labtech, a pioneer in the design and development of laboratory automation and liquid handling solutions, and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced a strategic partnership to provide automated workflows for single cell research. The collaboration will […]
read more
AI solutions from the DKFZ set new standards in medical image processing
Researchers at the German Cancer Research Center (DKFZ) have achieved outstanding success at this year’s world-leading forum for medical image processing and computer-assisted intervention. Two DKFZ departments competed in eight international AI competitions – and won seven of them. The successes cover key areas of oncology – from early detection and diagnosis to therapy support […]
read more
Role of intestinal bacteria in the development of colorectal cancer: Emmy Noether grant for DKFZ researcher Jens Puschhof
The German Research Foundation (DFG) is funding a new Emmy Noether project led by Jens Puschhof from the German Cancer Research Center (DKFZ). With this project, the junior researcher aims to decipher the role of certain intestinal bacteria in the earliest stages of colorectal cancer development and investigate how this process can be halted. The […]
read more
How immune cells become accomplices of tumors – Langener Wissenschaftspreis awarded to DKFZ researcher Daniel Kirschenbaum
Daniel Kirschenbaum has developed an experimental method for investigating immune responses in living organisms with high temporal resolution. The technique enabled him and his colleagues to reconstruct the temporal sequence of the immune response in malignant brain tumors for the first time. This opens up new perspectives for the development of targeted and temporally precise […]
read more
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
– Achieving Over 90% Accuracy, Wins First Place at GICHD-Sponsored Awards – Tokyo, Japan, October 29, 2025 — NEC Corporation (NEC; TSE: 6701) and the Cambodian Mine Action Center (CMAC, *1), the national institution responsible for landmine clearance activities in Cambodia, with assistance from JICA (*2), conducted a proof-of-concept using AI to predict landmine-contaminated areas. This […]
read more
Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
Ladenburg, Germany, 6 November 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that HDP-101 (INN: pamlectabart tismanitin), the Company’s lead ATAC candidate for the treatment of relapsed or refractory multiple myeloma, shows further clinical activity in Cohort 8 at a dose level of 140 µg/kg. These […]
read more
